ACADIA Pharmaceuticals Inc. Book value per Share

Book value per Share of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.


Highlights and Quick Summary

  • Book value per Share for the quarter ending December 30, 2020 was 3.94 (a -4.94% decrease compared to previous quarter)
  • Year-over-year quarterly Book value per Share decreased by -4.18%
  • Annual Book value per Share for 2020 was 3.99 (a -16.09% decrease from previous year)
  • Annual Book value per Share for 2019 was 4.75 (a 25.49% increase from previous year)
  • Annual Book value per Share for 2018 was 3.78 (a 38.39% increase from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of ACADIA Pharmaceuticals Inc.

Most recent Book value per Shareof ACAD including historical data for past 10 years.

Interactive Chart of Book value per Share of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 3.94 4.14 4.24 4.11 3.99
2019 4.53 4.72 2.69 2.91 4.75
2018 3.78 1.79 2.12 2.44 3.78
2017 2.73 3.08 3.4 3.76 2.73
2016 4.47 4.92 3.61 4.0 4.47
2015 1.99 2.26 2.55 2.85 1.99
2014 3.18 3.32 3.53 3.93 3.18
2013 2.12 2.02 2.18 1.01 2.12
2012 1.54 0.33 0.24 0.33 1.54
2011 0.45 0.53 0.62 0.76 0.45
2010 0.77 -0.0 0.08 0.77

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.